A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.
The committee spoke out against clinical applications of human germline genome editing and called for stronger global governance of the field.
The week’s biotech discoveries included eight mutations that contribute to cardiomyopathy and an enzyme that promotes basal-like breast cancer.
University of Wisconsin researchers have found an enzyme that acts as a key regulator of p53, which they believe may inspire cancer treatments ideas.
The ion channel-based chemogenetic platform involves pairing cell surface proteins with Chantix to selectively control neuronal activities.
Mammoth Biosciences is harnessing CRISPR to create diagnostic tools that can detect any biomarker containing DNA or RNA. It just added Cas14 to its arsenal.
Based on phase 2 data, a Georgetown University team showed that Tasigna reduces toxic protein clumps and restores dopamine metabolism in Parkinson's.
IBM researchers have identified four proteins in blood that can predict the buildup of amyloid-beta, a marker of Alzheimer's, with high accuracy.
British researchers discovered that blocking the protein MAP4K4, which is activated by stress signals, can reduce muscle damage from a heart attack.
A University of Chicago-led team found that a porphyria drug could work with the popular diabetes treatment metformin in triple-negative breast cancer.